



INSTITUT
DU CANCER
DE MONTRÉAL

L'Institut du cancer de Montréal présente



**Dr Alan Korman, Ph.D,
Vice President, Bristol-Myers Squibb**

Next Generation Immune Checkpoint Inhibitors

Alan received his PhD in Cellular and Developmental Biology from Harvard University (Cambridge, MA) in 1984, where he studied molecular immunology in the laboratory of Dr. Jack Strominger. From 1984 to 1989, he was a Whitehead Fellow at the Whitehead Institute, Massachusetts Institute of Technology (Cambridge, MA), where he continued his work in molecular immunology in association with the laboratory of Dr. Richard Mulligan. He was also a Chargé de Recherche at the Institut Pasteur (Paris, France) from 1990 to 1993, where he studied viral superantigens. Alan started his career in the biotechnology industry at Supragen in Colorado in 1993, which became part of NeXstar Pharmaceuticals. At NeXstar, he initiated the development of therapeutics targeting CTLA-4. Alan then joined Medarex in 2000, which was acquired by BMS in 2009. During his tenure at Medarex/BMS he and his team have spent their time studying the role of CTLA-4, PD-1 and PD-L1 and their roles in treating cancer. Under his supervision, Alan and his team have been responsible for the preclinical development for the first approved checkpoint inhibitor. More recently, Alan and his team have conducted preclinical research evaluating the combination of PD-1 and CTLA-4 in multiple tumor types. Today, Alan's team continues to conduct research of potential new immuno-oncology targets.

Mercredi le 28 mars 11h
CRCHUM, amphithéâtre du 5^e étage
R05.210

En collaboration avec le **CRCHUM**
CENTRE DE RECHERCHE

Institut du cancer de Montréal/CRCHUM
900 rue St-Denis, 10^e étage
Montréal, Québec H2X 0A9